Monalizumab

NK cell therapy, a promising cancer treatment, sees robust R&D with 140+ companies developing 160+ therapies. Key players include Amgen, Innate Pharma, Nektar Therapeutics, and others. Promising therapies like Bemarituzumab, Monalizumab, and NKTR-225 are in various clinical phases. Recent milestones include Immunitybio's CAR-NK cell therapy for NHL, Nkarta's NKX019 for AAV, and KGen Biotech's SNK01 advancing to Phase II.

ESMO Congress 2024 showcased PIONeeR trial addressing PD-1/PD-L1 resistance in NSCLC, Rome trial's genomic-guided therapy improving outcomes in metastatic solid tumors, and Prov-GigaPath AI model for cancer mutation prediction and tumor microenvironment analysis.

2024 NSCLC highlights: osimertinib sets new standard for EGFR-mutant, unresectable stage III disease; lorlatinib offers unprecedented PFS in ALK-positive tumors; perioperative nivolumab improves EFS over neoadjuvant-only; novel agents enhance neoadjuvant durvalumab efficacy.

John P. Sfakianos, MD discussed a study on BCG resistance in bladder cancer using spatial transcriptomics and imaging mass cytometry, leading to the ENHANCE trial combining durvalumab and monalizumab in BCG-resistant NMIBC patients, funded by BCAN.

Research at WCLC 2024 highlights potential treatments for NSCLC and ES-SCLC, including ivonescimab, aumolertinib, sacituzumab govitecan, N-803, durvalumab-based combinations, amivantamab plus lazertinib, ifinatamab deruxtecan, and sacituzumab govitecan. Trials show improved PFS, OS, and ORR with these treatments.

Durvalumab combined with datopotamab deruxtecan showed highest pathologic complete response rates in NeoCOAST-2 trial for resectable NSCLC, with 34.1% in arm 4, and a favorable safety profile.

Innate Pharma reported H1 2024 financials and clinical updates, including $12.3M revenue, $38.7M operating expenses, and $102.1M cash reserves. Lacutamab, an orphan drug, showed promising results in trials and received FDA designation. The ANKET platform advanced with SAR443579 in Phase 2 and IPH6501 in clinical trials. IPH45, an ADC targeting Nectin-4, is moving to Phase 1. The company aims to address unmet oncology needs and expects clinical data in the coming years.

Innate Pharma reports H1 2024 results: positive lacutamab Phase 2 in mycosis fungoides at ASCO 2024, NK-Cell engager SAR443579/IPH6101 advances to Phase 2, IPH45 (Nectin-4 ADC) progressing towards Phase 1, monalizumab data in early NSCLC presented at WCLC, cash position of €102.1 million, and a conference call at 2:00 p.m. CEST.

DelveInsight's 'Non-Small-Cell Lung Cancer Pipeline Insight 2024' covers 135+ companies and 150+ pipeline drugs, highlighting key players like BridgeBio Pharma, Daiichi Sankyo, and Merck. Prominent therapies include Trastuzumab deruxtecan, DS-1062a, and Pembrolizumab. Recent studies by Merck, AstraZeneca, and Gilead focus on Phase 3 trials for V940, Durvalumab, and Zimberelimab, respectively.

Adding novel agents to perioperative durvalumab for NSCLC led to higher pCR and mPR rates compared to historical rates with durvalumab and chemotherapy. The highest response rates occurred with the addition of Dato-DXd (pCR 34.1%, mPR 65.9%). All combinations demonstrated manageable safety profiles and surgical rates comparable to approved regimens.